Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:51 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 13,605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed Phase 2 Interventional Results available

A Two-Part Study of BOTOX® Therapy for Ischemic Digits

NCT01309802
View directory record Official record
Conditions
Raynaud's Disease
Interventions
onabotulinum toxin type-A
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Nov 1, 2026, 5:51 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Disitamab vedotin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
128
States / cities
Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 3 Interventional Results available

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

NCT04214639
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Bryant, Arkansas • Fremont, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

NCT00588341
View directory record Official record
Conditions
Melanoma, Skin Cancer, Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Nov 1, 2026, 5:51 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

NCT01014754
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Nov 1, 2026, 5:51 AM EST
Terminated Phase 1 Interventional Results available

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT04478994
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
TEPEZZA, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Nov 1, 2026, 5:51 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor

NCT07660666
View directory record Official record
Conditions
Melanoma
Interventions
Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Terminated Phase 1 Interventional

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

NCT02012231
View directory record Official record
Conditions
Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
Interventions
PLX8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

NCT02052141
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE 500, CINRYZE 1000
Biological
Lead sponsor
Shire
Industry
Eligibility
6 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Nov 1, 2026, 5:51 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

NCT05488483
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Multispectral Optoacoustic Tomography Imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Montvale, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Terminated Phase 2 Interventional Results available

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

NCT01059305
View directory record Official record
Conditions
Skin Cancer
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 1, 2026, 5:51 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Completed Not applicable Interventional

Non-Invasive Imaging for Cording in Breast Cancer Patients

NCT01427166
View directory record Official record
Conditions
Breast Cancer
Interventions
Non invasive venous ultrasound
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Nov 1, 2026, 5:51 AM EST
Completed No phase listed Observational

An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

NCT00291122
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib 400 mg BID
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 2 Interventional Results available

Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage

NCT00984022
View directory record Official record
Conditions
Abscess, Cellulitis
Interventions
Type of dressing - Iodoform, Type of dressing - Aquacel
Device
Lead sponsor
Valleywise Health
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Nov 1, 2026, 5:51 AM EST
Completed Phase 2 Interventional

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

NCT00001422
View directory record Official record
Conditions
Arthritis, Psoriatic, Psoriasis
Interventions
fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 5:51 AM EST
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

NCT03428802
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Completed Not applicable Interventional

Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain

NCT02439437
View directory record Official record
Conditions
Breast Cancer
Interventions
Psychosocial Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Nov 1, 2026, 5:51 AM EST
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Not yet recruiting Phase 2 Interventional

Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum

NCT07767864
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Bimekizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

NCT04971499
View directory record Official record
Conditions
Melanoma
Interventions
Dapansutrile, Pembrolizumab
Drug
Lead sponsor
April Salama, M.D.
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 1, 2026, 5:51 AM EST
Not listed Phase 1Phase 2 Interventional

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

NCT02990416
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
Biological · Radiation
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Nov 1, 2026, 5:51 AM EST